Cargando…

SAT-019 The Associations of Kisspeptin with Reproductive Hormones and Oocyte Maturation in Infertile Patients Who Underwent IVF Treatment

Kisspeptin has been recognized as a stimulatory factor of the hypothalamic-pituitary-gonadal (HPG) axis. Kisspeptin has been successfully used to trigger ovulation in in vitro fertilization (IVF) treatment (1). This study aimed to 1)compare reproductive hormones (FSH, LH, estradiol, progesterone, an...

Descripción completa

Detalles Bibliográficos
Autores principales: Qin, Lixian, Sitticharoon, Chantacha, Petyim, Somsin, Keadkraichaiwat, Issarawan, Sripong, Chanakarn, Sririwichitchai, Rungnapa, Maikaew, Pailin, Churintaraphan, Malika
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7208271/
http://dx.doi.org/10.1210/jendso/bvaa046.511
_version_ 1783530806213345280
author Qin, Lixian
Sitticharoon, Chantacha
Petyim, Somsin
Keadkraichaiwat, Issarawan
Sripong, Chanakarn
Sririwichitchai, Rungnapa
Maikaew, Pailin
Churintaraphan, Malika
author_facet Qin, Lixian
Sitticharoon, Chantacha
Petyim, Somsin
Keadkraichaiwat, Issarawan
Sripong, Chanakarn
Sririwichitchai, Rungnapa
Maikaew, Pailin
Churintaraphan, Malika
author_sort Qin, Lixian
collection PubMed
description Kisspeptin has been recognized as a stimulatory factor of the hypothalamic-pituitary-gonadal (HPG) axis. Kisspeptin has been successfully used to trigger ovulation in in vitro fertilization (IVF) treatment (1). This study aimed to 1)compare reproductive hormones (FSH, LH, estradiol, progesterone, and AMH), serum and follicular fluid kisspeptin between successful and unsuccessful clinical pregnancy in different stages of IVF treatment; 2) determine the correlations of serum or follicular fluid kisspeptin with reproductive hormones as well as biochemical and clinical outcomes; and 3) compare the levels of kisspeptin between serum and follicular fluid. In this study, 30 infertile female patients (age 26–40 years old) undergoing IVF treatment were recruited. Blood samples were collected at 3 different time points, the beginning of gonadotropin stimulation (the early follicular phase or T1), the scheduled day for ovum pick-up (OPU) (the late follicular phase or T2), and the day of OPU (T3). Meanwhile, biochemical and clinical parameters including the number of retrieved oocytes, matured oocytes, 2 pronuclear (2PN), and serum hCG were also determined. Moreover, fetus heart beat at 6 weeks of gestation was measured to classify the subjects into successful (n=10) and unsuccessful (n=20) clinical pregnancies. Serum AMH at T1 was significantly higher but serum FSH at T1 and T2 was significantly lower in the success group compared with the unsuccess group (P<0.05 all). Serum kisspeptin at T2 (P=0.09) and serum estradiol at T3 (P=0.05) tended to be higher in the success group compared with non-success group. Serum kisspeptin at T1 had negative correlations with the number of retrieved oocytes (R=-0.511), matured oocytes (R=-0.388), and 2PN (R=-0.451) (P<0.05 all). Serum kisspeptin at T2 had positive correlations with serum LH at T2 (R=0.455), serum kisspeptin at T3 (R=0.645), the number of retrieved oocytes (R=0.465), matured oocytes (R=0.432), and 2PN (R=0.445), and serum hCG levels (R=0.438) (P<0.05 all). Serum kisspeptin at T3 had positive correlations with serum estradiol at T3 (R=0.380), the number of retrieved oocytes (R=0.601), matured oocytes (R=0.565), and 2PN (R=0.562) (P<0.05 all). Follicular fluid kisspeptin levels had a negative correlation with serum FSH at T3 (R=-0.482) but a positive correlation with the number of matured oocytes (R=0.407) (P<0.05 all). Kisspeptin levels in the follicular fluid (3.34 ± 3.74 ng/ml) were significantly higher than in serum at T3 (0.51 ± 0.13 ng/ml) (P<0.01). As a result, kisspeptin at T2 was positively correlated with LH and clinical outcomes, suggesting that kisspeptin might play a role in augmentation of pre-ovulatory LH surge, improvement of oocyte maturation, and ovulation. Thus, kisspeptin might be used as a potential predictor of successful IVF treatment. Reference: (1) Abbara A, et al. J Clin Endocrinol Metab. 2015;100(9):3322–31.
format Online
Article
Text
id pubmed-7208271
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-72082712020-05-13 SAT-019 The Associations of Kisspeptin with Reproductive Hormones and Oocyte Maturation in Infertile Patients Who Underwent IVF Treatment Qin, Lixian Sitticharoon, Chantacha Petyim, Somsin Keadkraichaiwat, Issarawan Sripong, Chanakarn Sririwichitchai, Rungnapa Maikaew, Pailin Churintaraphan, Malika J Endocr Soc Reproductive Endocrinology Kisspeptin has been recognized as a stimulatory factor of the hypothalamic-pituitary-gonadal (HPG) axis. Kisspeptin has been successfully used to trigger ovulation in in vitro fertilization (IVF) treatment (1). This study aimed to 1)compare reproductive hormones (FSH, LH, estradiol, progesterone, and AMH), serum and follicular fluid kisspeptin between successful and unsuccessful clinical pregnancy in different stages of IVF treatment; 2) determine the correlations of serum or follicular fluid kisspeptin with reproductive hormones as well as biochemical and clinical outcomes; and 3) compare the levels of kisspeptin between serum and follicular fluid. In this study, 30 infertile female patients (age 26–40 years old) undergoing IVF treatment were recruited. Blood samples were collected at 3 different time points, the beginning of gonadotropin stimulation (the early follicular phase or T1), the scheduled day for ovum pick-up (OPU) (the late follicular phase or T2), and the day of OPU (T3). Meanwhile, biochemical and clinical parameters including the number of retrieved oocytes, matured oocytes, 2 pronuclear (2PN), and serum hCG were also determined. Moreover, fetus heart beat at 6 weeks of gestation was measured to classify the subjects into successful (n=10) and unsuccessful (n=20) clinical pregnancies. Serum AMH at T1 was significantly higher but serum FSH at T1 and T2 was significantly lower in the success group compared with the unsuccess group (P<0.05 all). Serum kisspeptin at T2 (P=0.09) and serum estradiol at T3 (P=0.05) tended to be higher in the success group compared with non-success group. Serum kisspeptin at T1 had negative correlations with the number of retrieved oocytes (R=-0.511), matured oocytes (R=-0.388), and 2PN (R=-0.451) (P<0.05 all). Serum kisspeptin at T2 had positive correlations with serum LH at T2 (R=0.455), serum kisspeptin at T3 (R=0.645), the number of retrieved oocytes (R=0.465), matured oocytes (R=0.432), and 2PN (R=0.445), and serum hCG levels (R=0.438) (P<0.05 all). Serum kisspeptin at T3 had positive correlations with serum estradiol at T3 (R=0.380), the number of retrieved oocytes (R=0.601), matured oocytes (R=0.565), and 2PN (R=0.562) (P<0.05 all). Follicular fluid kisspeptin levels had a negative correlation with serum FSH at T3 (R=-0.482) but a positive correlation with the number of matured oocytes (R=0.407) (P<0.05 all). Kisspeptin levels in the follicular fluid (3.34 ± 3.74 ng/ml) were significantly higher than in serum at T3 (0.51 ± 0.13 ng/ml) (P<0.01). As a result, kisspeptin at T2 was positively correlated with LH and clinical outcomes, suggesting that kisspeptin might play a role in augmentation of pre-ovulatory LH surge, improvement of oocyte maturation, and ovulation. Thus, kisspeptin might be used as a potential predictor of successful IVF treatment. Reference: (1) Abbara A, et al. J Clin Endocrinol Metab. 2015;100(9):3322–31. Oxford University Press 2020-05-08 /pmc/articles/PMC7208271/ http://dx.doi.org/10.1210/jendso/bvaa046.511 Text en © Endocrine Society 2020. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Reproductive Endocrinology
Qin, Lixian
Sitticharoon, Chantacha
Petyim, Somsin
Keadkraichaiwat, Issarawan
Sripong, Chanakarn
Sririwichitchai, Rungnapa
Maikaew, Pailin
Churintaraphan, Malika
SAT-019 The Associations of Kisspeptin with Reproductive Hormones and Oocyte Maturation in Infertile Patients Who Underwent IVF Treatment
title SAT-019 The Associations of Kisspeptin with Reproductive Hormones and Oocyte Maturation in Infertile Patients Who Underwent IVF Treatment
title_full SAT-019 The Associations of Kisspeptin with Reproductive Hormones and Oocyte Maturation in Infertile Patients Who Underwent IVF Treatment
title_fullStr SAT-019 The Associations of Kisspeptin with Reproductive Hormones and Oocyte Maturation in Infertile Patients Who Underwent IVF Treatment
title_full_unstemmed SAT-019 The Associations of Kisspeptin with Reproductive Hormones and Oocyte Maturation in Infertile Patients Who Underwent IVF Treatment
title_short SAT-019 The Associations of Kisspeptin with Reproductive Hormones and Oocyte Maturation in Infertile Patients Who Underwent IVF Treatment
title_sort sat-019 the associations of kisspeptin with reproductive hormones and oocyte maturation in infertile patients who underwent ivf treatment
topic Reproductive Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7208271/
http://dx.doi.org/10.1210/jendso/bvaa046.511
work_keys_str_mv AT qinlixian sat019theassociationsofkisspeptinwithreproductivehormonesandoocytematurationininfertilepatientswhounderwentivftreatment
AT sitticharoonchantacha sat019theassociationsofkisspeptinwithreproductivehormonesandoocytematurationininfertilepatientswhounderwentivftreatment
AT petyimsomsin sat019theassociationsofkisspeptinwithreproductivehormonesandoocytematurationininfertilepatientswhounderwentivftreatment
AT keadkraichaiwatissarawan sat019theassociationsofkisspeptinwithreproductivehormonesandoocytematurationininfertilepatientswhounderwentivftreatment
AT sripongchanakarn sat019theassociationsofkisspeptinwithreproductivehormonesandoocytematurationininfertilepatientswhounderwentivftreatment
AT sririwichitchairungnapa sat019theassociationsofkisspeptinwithreproductivehormonesandoocytematurationininfertilepatientswhounderwentivftreatment
AT maikaewpailin sat019theassociationsofkisspeptinwithreproductivehormonesandoocytematurationininfertilepatientswhounderwentivftreatment
AT churintaraphanmalika sat019theassociationsofkisspeptinwithreproductivehormonesandoocytematurationininfertilepatientswhounderwentivftreatment